ArticleCardiology and therapy2025
Cracking the Zip Code: Uncovering the Link Between Socioeconomic Status and Transcatheter Aortic Valve Replacement Outcomes.
Article in Cardiology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThere is a well-known correlation between lower socioeconomic status and health outcomes. Patient zip codes and the Centers for Disease Control and Prevention's (CDC) Social Vulnerability Index (SVI) can be surrogates for income and socioeconomic status to compare outcomes following transcatheter aortic valve replacement (TAVR).
methodsWe performed a retrospective study among patients who underwent TAVR at the University of Illinois at Chicago (UIC) in Chicago, Illinois, between March 2018 and June 2023. Using income data from the Census Bureau and the SVI, we assigned patients to two income groups: lower (LIG) or higher (HIG). Primary outcomes were composite major adverse cardiac events (MACE) (consisting of cardiovascular death, myocardial infarction, or cerebrovascular accident) and all-cause death. Secondary outcomes included congestive heart failure exacerbations and major bleeding events. Outcomes were analyzed at 30 days, 6 months, and 12 months.
resultsWe analyzed 276 patients; the LIG comprised 222 (80%) of these patients. No significant differences between groups were found in the primary or secondary outcomes post-TAVR at the 6- or 12-month interval. There were significant differences in SVI between those experiencing bleeding events at 12 months. There were no differences in primary outcomes between racial groups in a subanalysis.
conclusionFollowing TAVR, patients in the LIG and HIG had no differences in adverse events at 6 and 12 months post-TAVR. Patients in regions with higher SVI (more vulnerable regions) had higher periprocedural bleeding events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.